Phase 2 Relapsed and Refractory Clinical Trials
5 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–5 of 5 trials
Recruiting
Phase 2
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
Follicular LymphomaRelapsed and Refractory Follicular Lymphoma
Sun Yat-sen University32 enrolled3 locationsNCT04989621
Recruiting
Phase 2
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
Relapsed and Refractory Multiple Myeloma
University of Miami33 enrolled3 locationsNCT05530421
Recruiting
Phase 2
A Phase I/II trial to determine the Safety, Toxicity and Efficacy of Iodine-131-Rituximab and the Histone Deacetylase Inhibitor Panobinostat in Relapsed and Refractory Indolent B-cell Lymphoma
Relapsed and Refractory Indolent B-cell Lymphoma
Peter MacCallum Cancer Centre30 enrolled1 locationACTRN12612000746831
Withdrawn
Phase 2
Lenalidomide with epigenetic therapy in relapsed or refractory Acute Myeloid Leukaemia (AML)-Phase II
relapsed and refractory acute myeloid leukaemia
Australasian Leukaemia and Lymphoma Group120 enrolled1 locationACTRN12612000312842
Completed
Phase 2
A Pilot Study to Evaluate the Safety and Efficacy of Rituximab in Combination with Out-Patient Based Vinorelbine, Gemcitabine and Pegfilgrastim (VGF)/Pegfilgrastim, Gemcitabine, Ifosfamide and Vinorelbine (F-GIV) Salvage Therapies in the treatment of Relapsed/Refractory CD20+ Lymphomas.
Relapsed and refractory CD20+ lymphoma
Associate Professor Andrew Spencer12 enrolled1 locationACTRN12606000386538